• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    9/7/22 8:21:34 AM ET
    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNA alert in real time by email

     

    Gainers

    • BioVie (NASDAQ:BIVI) stock increased by 32.3% to $4.55 during Wednesday's pre-market session. The company's market cap stands at $130.2 million.
    • bioAffinity Technologies (NASDAQ:BIAF) shares increased by 30.61% to $7.04. The market value of their outstanding shares is at $19.2 million.
    • Imara (NASDAQ:IMRA) stock moved upwards by 23.93% to $1.45. The market value of their outstanding shares is at $38.1 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 18.37% to $3.93. The market value of their outstanding shares is at $18.8 million.
    • Spero Therapeutics (NASDAQ:SPRO) shares increased by 17.69% to $1.33. The company's market cap stands at $46.6 million.
    • iSpecimen (NASDAQ:ISPC) stock rose 15.42% to $2.47. The market value of their outstanding shares is at $21.9 million.

    Losers

    • Shuttle Pharmaceuticals (NASDAQ:SHPH) stock decreased by 22.1% to $22.2 during Wednesday's pre-market session. The market value of their outstanding shares is at $294.8 million.
    • Allena Pharma (NASDAQ:ALNA) stock decreased by 12.11% to $0.06. The market value of their outstanding shares is at $7.8 million.
    • Rubius Therapeutics (NASDAQ:RUBY) stock decreased by 11.13% to $0.87. The company's market cap stands at $78.7 million.
    • Organovo Holdings (NASDAQ:ONVO) stock declined by 10.31% to $2.35. The company's market cap stands at $20.4 million.
    • DBV Technologies (NASDAQ:DBVT) stock decreased by 10.22% to $2.11. The market value of their outstanding shares is at $396.3 million.
    • Cidara Therapeutics (NASDAQ:CDTX) stock decreased by 10.13% to $0.61. The company's market cap stands at $42.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNA
    $BIVI
    $CDTX
    $DBVT

    CompanyDatePrice TargetRatingAnalyst
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    Cidara Therapeutics Inc.
    $CDTX
    10/16/2025$190.00Overweight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    10/10/2025$200.00Overweight
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    6/18/2025$41.00Buy
    H.C. Wainwright
    More analyst ratings

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Rajavelu Esther sold $207,484 worth of shares (87,917 units at $2.36), decreasing direct ownership by 8% to 1,012,091 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    2/9/26 9:31:37 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Keutzer Timothy sold $44,019 worth of shares (18,652 units at $2.36), decreasing direct ownership by 2% to 742,506 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    2/9/26 9:09:39 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Lawlor Sally Bridget

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:24:03 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

    ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company

    3/19/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

    CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di

    3/18/26 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

    Woburn, Massachusetts--(Newsfile Corp. - March 16, 2026) - iSpecimen Inc. (NASDAQ:ISPC) (the "Company"), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the responsiveness and capabilities of its site network. Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected approximately 500 influenza swab samples over a period of several weeks to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnarou

    3/16/26 7:47:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Cidara Therapeutics from Outperform to Sector Perform

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    SEC Filings

    View All

    iSpecimen Inc. filed SEC Form 8-K: Other Events

    8-K - iSpecimen Inc. (0001558569) (Filer)

    3/13/26 5:00:30 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed by Quoin Pharmaceuticals Ltd.

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    3/11/26 4:30:34 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by iSpecimen Inc.

    DEFA14A - iSpecimen Inc. (0001558569) (Filer)

    3/3/26 4:05:22 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Leadership Updates

    Live Leadership Updates

    View All

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

    Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased

    10/30/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNA
    $BIVI
    $CDTX
    $DBVT
    Financials

    Live finance-specific insights

    View All

    Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

    CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di

    3/18/26 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Jan. 22, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH.  Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $0.50284 36.87 % 0.00 % 50.00 % 01/23/2026 01/27/2026 -4.93 % N/A -10.58 % Bitwise MARA Option Income Strategy ETF IMRA $0.20782 14

    1/22/26 4:21:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care